AU601510B2 - Preparation of bacterium pili subunits and vaccines containing pili subunits - Google Patents
Preparation of bacterium pili subunits and vaccines containing pili subunits Download PDFInfo
- Publication number
- AU601510B2 AU601510B2 AU80890/87A AU8089087A AU601510B2 AU 601510 B2 AU601510 B2 AU 601510B2 AU 80890/87 A AU80890/87 A AU 80890/87A AU 8089087 A AU8089087 A AU 8089087A AU 601510 B2 AU601510 B2 AU 601510B2
- Authority
- AU
- Australia
- Prior art keywords
- pili
- subunits
- solution
- bacteria
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000894006 Bacteria Species 0.000 title claims description 52
- 229960005486 vaccine Drugs 0.000 title claims description 34
- 238000002360 preparation method Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims description 69
- 239000000243 solution Substances 0.000 claims description 34
- 239000006187 pill Substances 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 10
- 239000008188 pellet Substances 0.000 claims description 9
- 238000003306 harvesting Methods 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 238000010979 pH adjustment Methods 0.000 claims description 7
- 230000000717 retained effect Effects 0.000 claims description 7
- 239000006174 pH buffer Substances 0.000 claims description 6
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 5
- 238000011033 desalting Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000588621 Moraxella Species 0.000 claims description 4
- 241000588650 Neisseria meningitidis Species 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 4
- 241000607768 Shigella Species 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229940031626 subunit vaccine Drugs 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 9
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 6
- 239000006194 liquid suspension Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 241000588622 Moraxella bovis Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010000916 Fimbriae Proteins Proteins 0.000 description 4
- 239000007994 TES buffer Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001548492 Coreus Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186246 Corynebacterium renale Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- -1 ammonium sulfate Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000001224 bacterial fimbriae Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
zAxMAnjs bdouw ~apjqo o 11125 1 1.6 ZAXMAfIScDdONWITrIHoa3DsV Id OL I I I 1 7 K 01 ,FefQ 130 FORM 10 COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 COMPLETE SPECIFICATION
(ORIGINAL)
FOR OFFICE USE: Class Int Class Complete Specification Lodged: Accepted: Published: ,qt t Priority:
I
LI L i-YI1 1:; Related Art: Name and Address of Applicant: Address for Service: ImmunoMed Corporation 5910-G Breckenridge Parkway Tampa Florida 33610 UNITED STATES OF AMERICA Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia 3i r Complete Specification for the invention entitled: Preparation of Bacterium Pili Subunits and Vaccines Containing Pili Subunits The following statement is a full description of this invention, including the best method of performing it known to me/us 5845/3
-L
I
ABSTRACT
A method for obtaining bacterium pill subunits directly from specified bacteria is disclosed and claimed. Dependent upon the bacterium from which the pili subunits are to be obtained, the pH of extraction solutions will be adjusted accordingly. Pili subunits obtained in accord with the method of this invention are useful for preparing vaccines which exhibit good protection against heterologous strain infections.
4 tt S /-2 I 44 i t S3N/45F -2- 0 e Q JTA:113F BACKGROUND OF THE INVENTION Field of the Invention.
The present invention relates to a unique method for obtaining bacterium pili subunits suitable for use in preparing a vaccine.
Description of the Prior Art Pili, also referre.d to as Fimbriae, are hairlike organelles attached to the outer surface of bacteria, Pili are composed of many identical protein subunits arranged in a helical array. For pathogenic bacteria, [j pili are important for virulence, and their role appears to be that of promoting adherence of the bacterium to the host'K tissues. That is to say, the importance of pilli lies in the fact that they participate in the pathogenic process of many disease causing bacteria. The first step in any bacterial infection is attachment of the bacteria to the host's tissues.
The second step is the colonization phase during which the bacteria divide and increase their numbers at or near the site of initial attachment. The StC third step is the actual pathogenic step which can vary from one bacterial species to the next. For example, in the case of enterotoxogenic E. coli, toxins are secreted by the bacteria which damage host tissue and cause fluids to move into the gut resulting in diarrhea.
I 2,0 As revealed in the prior art patents and professional publications, several vaccines have already been developed and are being developed utilizing pill as immunogens. Because pili are important in the early adhesion stages of infections, these vaccines are thought to act to prevent the subsequent colonization step and, thereby, to subvert the infection.
Literally all known vaccines today contain intact pili.
The strains of bacteria used to prepare such vaccines are selected on the basis of pilus serotype. In the case of N. gonorrhoeae bacteria, the serotype of these pili is highly variable. Therefore, great care must be c used in the selection of the strains selected to produce the vaccine to obtain the broadest range of protection. There is a low level of cross reactivity among the pili produced by the different strains, but compared to the antigenicity of the variable portions of the pilli subunit, this is minor. Thus, although such an "intact pilus" vaccine gives good protection against infection with the homologous strain of bacteria, it gives much poorer protection against heterologous strains.
Exemplar prior art patent teachings concerned with vaccines utilizing a pili component are Brinton's U.S. Pat. No. 4,237,115 and U.S. Pat. No.
4,298,597 to Acres. Both these patents disclose vaccines of an "intact 3 pilus" type. Other analogous prior art disclosures are contained in the following U.S. Pat. Nos.: Homma, U.S. Pat. No. 3,928,565 Fullerton, U.S. Pat. No. 4,199,565 Buchanan, U.S. Pat. No. 4,203,971 Karkhanis, U.S. Pat. No. 4,220,638 Helting, U.S. Pat. No. 4,271,147 Just as a study of prior patent literature reveals pertinent disclosures, so also does a review of prior professional literature. For example, this inventor recognized that pili might be further degraded into subunits in his paper titled, "Isolation of and Some Physical-Chemical Properties of Pili Isolated from Type 2 Colonies of Neisseria gonorrhoeae" which appeared in PILI, D. E. Bradley, Ed., International Conferences in Pili, Washington, D.C. 1978. Further pertinent prior art disclosure has also been made by this inventor in his article titled "Structure of Common Pili from Escherichia coli", JOURNAL OF BACTERIOLOGY, Vol. 138, No. 3, June 1979 at 969-975. In the second article, this inventor discusses not only a method for obtaining pili, but also means for disrupting purified pili into subunits, or pilin. Isaacson, et al, in their article titled, S, 2.0 "Escherichia coli K99 Pili Are Composed of One Subunit Species", FEMS MICROBIOLOGY LETTERS, 12 at 229-232 (1981), confirm the work of this inventor as reported by him in Volume 138 of the JOURNAL OF BACTERIOLOGY, S" and present further findings concerning the structure of K99 subunits.
'More recently, Korhonen and Rhen, in their article titled, "Bacterial Fimbriae as Vaccines", ANNALS OF CLINICAL RESEARCH, Vol. 14 at 272-277 (1982), have recognized the limitations of "intact pilus" vaccines and have S recognized that a subunit vaccine would probably exhibit greater efficacy against heterologous strains.
Thus, it is clear that vaccines prepared from intact, or whole, pili are well known in the prior art. It is also accurate to state that the prior art has recognized the hypothetical desirability of preparing pili subunit vaccine. It is postulated that in such a subunit vaccine, the antigenic zones (epitopes) which are identical for the pili from one strain to the next would be exposed. Accordingly, such a subunit vaccine would permit a greater degree of cross protection against different bacterial strains.
The primary difficulties associated with producing a pili subunit vaccine have basically involved determining a commercially-acceptable 4 procedure for deriving the pill subunits so that a subunit vaccine can be readily prepared in accord with accepted manufacturing processes.
SUMMARY OF THE INVENTION The present invention relates to a unique method for harvesting pill subunits, or pilin, directly from bacteria in a liquid suspension.
Thus according to a first embodiment of the inivention there is provided a method for obtaining bacterium pili subunits suitable for use in preparing a vaccine, said method comprising the steps of: a. harvesting the bacteria from their growth medium in a buffer solution of substantially neutral pH; b. adjusting the pH of the bacterial solItion to about pH 9-11; c. agitating the pH 9-11 bacterial solution to disrupt the pill; d. centrifuging the pili-containing solution; discarding the pellet formed during centrifugation step d; f. adjusting the pH of the pili-containing supernatant retained from step e to above about pH 11.25 to obtain a pili subunit-containing solution; deft g. adjusting the pH of the subunit-containing solution to substantial neutrality; and h. adjusting the concentration of the pill' subunit-containing material from step g to obtain the pili subunits suitable for use in preparing a vaccine.
s| *Pill subunits thus obtained are extremely useful in preparing vaccines which exhibit increased cross protection against different bacterial strains. To understand the advantage of the pill subunits and d vaccines containing pili subunits, one must have some understanding of the structure and function of pili. A pilus subunit expresses both hypervariable and constant regions. The hypervariable region is on the outer surface of the intact structure, and it is this region that causes the wide range in serotype. The advantage from the bacterium's point of view is that the host, once immunized against one strain of the bacteria can be reinfected by a different strain. This may significantly explain the high rate of recidivism observed in veneral disease clinics.
Preparation and use of pill subunits in accord with this invention actually maximizes the constant region of a pilus subunit. These constant regions are essentially the same regardless of the bacterial strain and are important for at least two pili functions. One of these functions is to 5a confer the basic structure to the intact plus. The other confers biological activity. Rationale for using pili subunits is that in this form of the antigen, more of the constant regions of the subunits are exposed, and a stronger antibody response toward those sites can be expected. Since a constant region is found in pili of one class from related species a greater degree of cross-reactivity derives from their use. Furthermore, since these constant regions are responsible for the biological activity of the pili, that is, adherence to the host's tissue, antibodies directed to such sites should be more effective in ameliorating the infection.
As a direct result of experimental work conducted by this inventor utilizing the procedures and methods set forth in greater detail hereinafter, pill subunits have been obtained from Neisseria gonorrhoeae.
r Moraxella bovis, and Escherichia coli bacteria. With specific regard to the E. coli, subunits of type 1 pili were obtained. In all cases, the pili subunits were harvested directly from their bacteria in liquid suspension according to a relatively simple, economical and yet efficient method.
Vaccines prepared from the N. gonorrhoeae pill have demonstrated efficacy I against gonorrhea, and it is anticipated, as a result of this inventor's t C
I\I
S, MS1944c f ij 1
A
work, that a vaccine prepared from subunits will demonstrate similar efficacy against a broader range of gonorrhea infections. Vaccines prepared from M. bovis pill have demonstrated efficacy against infectious bovine keratoconjunctivitis, and it is similarly anticipated that subunit vaccines will have a broader range of efficacy. E. coli strains causing scours in. cattle, diarrhea in pigs, and urinary infections in humans have pill closely related to type 1 pili. Thus, a pili subunit vaccine could be prepared against all these infections.
As a result of this inventor's work to date, it seems clear that pili subunits can be obtained from and subunit vaccines can be developed against, virtually any piliated pathogenic bacteria. For example, pili subunits may be obtained from Neisseria meningitidis in accord with the method utilized for obtaining pili subunits for N. gonorrhoeae and Moraxella specie. It is believed that essentially the same method may be S utilized to obtain pili subunits from Pseudomonas aeruginosa. Pili subunits can be obtained directly from Salmonella specie and Shigella specie according to a method substantially similar to that followed in obtaining E. coli type 1 pili subunits. It is accordingly believed that similar pili subunits may be obtained, and subunit vaccines prepared, from many of the following piliated pathogenic bacteria: GRAM NEGATIVE GRAM POSITIVE Klebsiella pneumoniae Corynebacterium diptheriae Proteus specie Corynebacterium renale Vibrio choleroe Actinomycex specie Aeromonas specie Fusobacterium necrophorum Borderella pertussis Streptococcus pyogenes Bacteroides nudosus Streptococcus sanguis Legionella pneumophila Propionibacterium genes Pasteurello muhocido Bacillus coreus (spores) Yersinia enterocolitico Moraxella bovis Acinetobacter specie Providencia specie In all cases, once the pill subunits have been obtained, the corresponding pili subunit vaccine is prepared in accord with normal technology and procedures. Accordingly, subunit vaccines prepared in accord with this invention would consist essentially of a normal saline or buffer solution containing the pili subunits and an appropriate adjuvant.
6 Two basic methods for obtaining pili subunits in accord with the scope of this invention have been determined and are set forth in greater detail hereinafter. However, both methods are quite similar in that they both provide means for obtaining, or harvesting, the pili subunits directly from their bacteria in liquid suspension. It has been determined that, dependent upon the bacterium from which the pili subunits will be obtained, controlled adjustment of the pH of liquid suspension phases will result not only in separation of the intact pili from their bacteria, but also in disruption of the separated pili into the desired pil subunits. In all cases, the initial step of the method of this invention involves growth of the selected bacteria in accord with standard procedures. The bacteria are then harvested directly into virtually any neutral buffer solution. For example, N-tris (hydroxymethyl)methyl-2-aminoethane sulfonic acid (TES) may be used to prepare a buffer adjusted to pH 6-8, and preferably pH 7.0, with sodium hydroxide. This TES buffer has proved to be quite suitable for harvesting the bacteria. Then, for N. gonorrhoeae, N. meningitidis, and Moraxella specie, the pH of the solution is raised to about pH 9-11 and agitated to disrupt the pili from the bacteria. This solution is centrifuged and the resulting pellet is discarded, retaining the S 0. pili-containing supernatent. The pili-containing supernatant is then adjusted so that its pH is raised to above pH 11.25 resulting in disruption of the pilli into subunits. The pili subunits are caused to separate from the high pH solution, and subsequent centrifugation results in the formation of a pili subunit pellet which is suitable for use in preparing a pilli subunit vaccine. In the case of E. coli, Salmonella specie, and Shigella specie bacteria, a slight modification of the method is necessary in order to separate the pili and disrupt them into the desired subunits.
Following initial harvesting of the bacteria in the TES buffer solution, the pH is adjusted to below pH 2, and preferably about pH 1.8, by the addition of hydrogen chloride. This low pH solution is then placed into a boiling water bath for about five minutes resulting in the disruption of the intact pili. After removal from the boiling water bath, the low pH solution is allowed to cool to room temperature, and its pH is then adjusted to about pH 10 as by the addition of sodium hydroxide. The pH solution is centrifuged, and the pellet formed during centrifugation is discarded while the pili-containing supernatant is retained. Adjusting the pH of the supernatant to substantial neutrality and adding a salt such as ammonium sulfate permits harvesting of the pilus subunits as a pellet 7 following centrifugation as described above. The resulting pill subunit pellet may then be prepared into a subunit vaccine.
It is also to be understood that as used throughout this specification, the term "subunit" is not to be limited to a monomeric molecular configuration. In fact, this inventor has determined that the apparent configuration of N. gonorrhoeae pili subunits is hexomeric. Thus, the term "subunit" is meant to encompass oligomers as well as monomers.
More specific details of the method of this invention will be set forth in the examples presented hereinafter. The invention accordingly comprises the several steps and the relation of one or more of such steps with respect to each of the others which will be exemplified in the method hereinafter disclosed and the scope of the invention will be indicated in the claim.
DETAILED DESCRIPTION :i sr tThe present invention relates to a method for obtaining bacterium pilli subunits directly from the bacteria in a liquid suspension phase. The method of this invention, with slight modifications as set forth in greater detail hereinafter, has been demonstrated to be suitable for use in obtaining pili subunits from a broad variety of piliated pathogenic I 20 bacteria. Adjustments to method parameters involving pH adjustment of serial liquid suspensions are made dependent upon the bacterium from which j tr the pili subunits are being obtained. The pili subunits, or pilin, obtained in accord with the method of this invention are then utilized to prepare vaccines exhibiting efficacy against different bacterial strains.
The suhunit vaccines per se are prepared in accord with normal methodology, and consist essentially of a normal saline, or buffer, solution including the pili subunits and an appropriate adjuvant. The method of this invention is particularly characterized by its steps whereby pili subunits may be obtained directly from the bacteria in a relatively simple and certainly economical manner; no detergents are utilized in obtaining the pili subunits; and, unlike intact pili preparations, the pili subunits can be sterilized by filtration. This is especially important with regard to commercial preparation of subunits and subunit vaccines.
The following examples, then, are set forth in order to describe more fully the method of the present invention.
EXAMPLE I This example sets forth a preferred method for obtaining E. coli type 1 pili subunits. The F-N1-3 substrain of E.coli K-12 was used 8 1 exclusively. The bacteria were grown in Lennox broth consisting of 10 g of sodium chloride, 1 g of dextrose monohydrate, 10 g of tryptone (Difco Laboratories, Detroit, Mich.), and 5 g of yeast extract (Difco), made up to 1 liter with distilled water. The bacteria were harvested at mid- to late-log phase by centrifugation.
The bacteria, harvested by centrifugation from 3 liters of medium were suspended in 100 ml of TES buffer at about pH 7. The buffered bacteria solution/suspension was then adjusted to about pH 1.8 by the addition of hydrogen chloride. The resulting pH 1.8 material was then immersed in a boiling water bath for about five minutes, removed from the bath, and allowed to cool to room temperature.
Having cooled to room temperature, the solution was then adjusted to about pH 6-10 by the addition of sodium hydroxide. Centrifugation of the pH 6-10 solution resulted in the formation of a pellet which was discarded, and the pilus subunit-containing supernatant was retained.
9*9 The subunit-containing supernatant was then adjusted to about neutrality (pH This final liquid phase was then concentrated to yield E. coli type 1 pili subunits from which a vaccine was prepared. The vaccine was prepared according to standard methodology and consisted essentially of normal saline solution, pili subunits and an appropriate adjuvant for the patient/animal to which the vaccine will be administered.
Because of the relatively small si.'e of the pill subunits, sterilization lt was accomplished by using a filter having a pore size of about 0.22 microns. Concentration may be accomplished by centrifugation, dialysis, the use of a desalting column, addition of a salt such as ammonium sulfate, or combinations of the above. Thus, the term "concentration" does include adjusting the pH to substantial neutrality.
EXAMPLE II The method of Example I was repeated, but concentration of the pilli subunits was accomplished by dialyzing the final liquid phase against a neutral pH buffer.
EXAMPLE III The method of Example I was repeated, but concentration of the pili subunits was accomplished by utilizing a desalting column to remove high pH buffer.
EXAMPLE IV This example sets forth a preferred method for obtaining Neisseria gonorrhoeae pili subunits. The N. gonorrhoeae bacteria were grown 9
A
according to standard procedures and were harvested into a TES buffer solution at about pH 7. The pH of the bacteria solution/suspension was then raised to about pH 9-11, and preferably about pH 10.25-10.5, by the addition of ethanolamine buffer. This increased pH phase was then vortexed lightly to break the intact pili from the bacteria.
Following agitation, the increased pH phase was centrifuged, and the resulting pellet was discarded. The intact pili remained in the supernatant. Next, the pH of the pili-containing supernatant was raised to above pH 11.25 resulting in disruption of the intact pili into pili subunits, or pilin. Concentration yielded a quantity of pili subunit material suitable for preparing a N. gonorrhoeae pili subunit vaccine. The vaccine was prepared as set forth in Example 1, and was sterilized by filtration as previously described.
EXAMPLE V The method of Example IV was repeated, and concentration of the pili subunits was accomplished by dialyzing the final liquid phase against a neutral pH buffer.
SEXAMPLE VI The method of Example IV was repeated, and concentration of the pili 20 subunits was accomplished by utilizing a desalting column to remove high pH buffer.
EXAMPLE VII S'The method of Example V was repeated, but Moraxella bovis bacteria were utilized as the starting material. Thus, pili subunits of M. bovis were obtained and used to prepare a vaccine against infectious bovine keratoconjunctivitis.
In addition to the examples set forth above, additional laboratory experimentation and applied theory suggests that pili subunits may be obtained from Neisseria meningitidis and from Pseudomonas aeruginosa in accord with the methods of Examples IV, V or VI. Corresponding pili subunit vaccines may be similarly prepared. In similar fashion it is believed that pili subunits and the corresponding pili subunit vaccines may be obtained for other members of the Moraxella specie in accord with the method of Example VII. Finally, the methods of Examples I, II and III all appear to be suitable for obtaining pili subunits and corresponding pili subunit vaccines for Salmonella specie and Shigella specie.
It will thus be seen that the objects set forth above, among those made apparent from the preceding description, are efficiently attained, and '10 since certain changes may be made in carrying out the above method without departing from the scope of the invention, it is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense.
It is also to be understood that the following claims are intended to cover all of the generic and specific features of the invention herein described, and all statements of the scope of the invention which as a matter of language, might be said to fall therebetween.
It St 11
Claims (24)
1. A method for obtaining bacterium pili subunits suitable for use in preparing a vaccine, said method comprising the steps of: a. harvesting the bacteria from their growth medium in a buffer solution of substantially neutral pH; b. adjusting the pH of the bacterial solution to about pH 9-11; c. agitating the pH 9-11 bacterial solution to disrupt the pili; d. centrifuging the pill-containing solution; e. discarding the pellet formed during centrifugation step d; f. adjusting the pH of the pili-containing supernatant retained from step e to above about pH 11.25 to obtain a pili subunit-containing solution; g. adjusting the pH of the subunit-containing solution to substantial neutrality; and h. adjusting the concent-ation of the pili subunit-containing material from step g to obtain the pili subunits suitable for use in preparing a vaccine.
2. A method as in claim 1 wherein the bacteria are harvested in a buffer solution at pH 6-8.
3. A method as in claim 2 wherein the bacteria are harvested in a buffer solution at about pH 7.
4. A method as in claim 1 wherein the bacteria are selected from the group consisting of Neisseria gonorrhoeae, Neisseria meningitidis, an Moraxella specie.
A method as in claim 4 wherein the bacteria are N. gonorrhoeae
6. A method as in claim 5 wherein the bacteria are harvested in a buffer solution at about pH 7.
7. A method as in claim 5 wherein the bacteria solution is adjust to about pH 10.25-10.5 at step b.
8. A method as in claim 1 wherein said final pH adjustment is accomplished by adding a salt to the pili subunit-containing solution.
9. A method as in claim 8 wherein said salt comprises ammonium d ed sulfate.
A method as in claim 1 wherein said final pH adjustment is accomplished by dialyzing the pili subunit-containing solution against a neutral pH buffer solution.
11. A method as in claim 1 wherein said final pH adjustment is accomplished by using a desalting column to remove high pH buffer added in 12 5845/3 F '1 iiu p i adjusting step f.
12. A method as in claim 1 further comprising the step of sterilizing the pili subunits by filtration.
13. A method for obtaining bacterium pili subunits suitable for use in preparing a vaccine, said method comprising the steps of: a. harvesting b.acterials selected from the group consisting of Escherichia coli, Salmonella specie, and Shigella specie from their growth medium in a buffer solution of substantially neutral pH; b. adjusting the pH of the bacterial solution to below about pH 2; c. placing the lowered pH bacterial solution in a boiling water bath for about 5 minutes; d. removing the heated solution from the bath and allowing it to cool to room temperature; e. adjusting the pH of the cooled solution from step d to about pH 6-10; f. centrifuging the solution of step e; g. discarding the peilet formed during centrifugation step f; h. adjusting the pH of the subunit-containing supernatant retained from step g to substantial neutrality; and i. adjusting the concentration of the pilli subunit-containing material from step h to obtain the pilli subunits suitable for use in preparing a vaccine.
14. A method as in claim 13 wherein the bacteria are E. coli.
A method as in claim 14 wherein the bacteria are harvested in a buffer solution at about pH 6-8.
16. A method as in claim 14 wherein the pH of the bacterial solution is adjusted by adding hydrogen chloride.
17. A method as in claim 16 wherein the pH is adjusted to about pH 1.8.
18. A method as in claim 14 wherein the pH of the cooled solution is adjusted by adding sodium hydroxide.
19. A method as in claim 14 wherein said final pH adjustment of the pilli subunits is accomplished by adding a salt to the supernatant retained from step g.
A method as in claim 14 wherein said final pH adjustment of the pilli subunits is accomplished by dialyzing the supernatant retained from step g against a neutral pH buffer solution.
21. A method as in claim 14 wherein said final pH adjustment of the 13 14 pill subunits is accomplished by using a desalting column to remove high pH buffer added in adjusting step e.
22. A method as in claim 13 further comprising the step of sterilizing the pili subunits by filtration.
23. A method for obtaining bacterium pili subunits suitable for use in preparing a vaccine, said method being substantially as hereinbefore described with reference to any one of the Examples.
24. Bacterium pili whenever prepared by a method as defined in any one of claims 1 to 23. DATED this TWENTY-EIGHTH day of JUNE 1990 ImmunoMed Corporation Patent Attorneys for the Applicant SPRUSON FERGUSON I 1 «1 i11 TMS/944c
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU80890/87A AU601510B2 (en) | 1987-11-06 | 1987-11-06 | Preparation of bacterium pili subunits and vaccines containing pili subunits |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU80890/87A AU601510B2 (en) | 1987-11-06 | 1987-11-06 | Preparation of bacterium pili subunits and vaccines containing pili subunits |
Publications (2)
Publication Number | Publication Date |
---|---|
AU8089087A AU8089087A (en) | 1989-05-11 |
AU601510B2 true AU601510B2 (en) | 1990-09-13 |
Family
ID=3759828
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU80890/87A Ceased AU601510B2 (en) | 1987-11-06 | 1987-11-06 | Preparation of bacterium pili subunits and vaccines containing pili subunits |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU601510B2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1853883A (en) * | 1982-09-02 | 1984-03-08 | Unilever Plc | Production of antibodies |
AU2066283A (en) * | 1982-10-29 | 1984-05-03 | Bactex Inc. | Vaccine against moraxella bovis |
AU4299485A (en) * | 1984-05-02 | 1985-11-28 | Symbicom Aktiebolag | Adhesin antigens, antibodies and dna fragment encoding the antigen, methods and means for diagnosis and immunization etc |
-
1987
- 1987-11-06 AU AU80890/87A patent/AU601510B2/en not_active Ceased
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1853883A (en) * | 1982-09-02 | 1984-03-08 | Unilever Plc | Production of antibodies |
AU2066283A (en) * | 1982-10-29 | 1984-05-03 | Bactex Inc. | Vaccine against moraxella bovis |
AU4299485A (en) * | 1984-05-02 | 1985-11-28 | Symbicom Aktiebolag | Adhesin antigens, antibodies and dna fragment encoding the antigen, methods and means for diagnosis and immunization etc |
Also Published As
Publication number | Publication date |
---|---|
AU8089087A (en) | 1989-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ibrahim et al. | Method for the isolation of highly purified Salmonella flagellins | |
DE69125769T2 (en) | Nucleotide sequence coding for an outer membrane protein of Neisseria meningitidis and use of this protein for the production of vaccines | |
RU2325184C2 (en) | Improvement of bacteria outer membrane vesicle | |
EP0088303B1 (en) | Process for the preparation of polysaccharide-protein complexes from bacterial envelopes, products obtained and immunogenic compostions containing them | |
US4454116A (en) | Immunization of humans against enterotoxogenic infection by Escherichia coli | |
US5618541A (en) | Vaccine against Neisseria meningitidis infections | |
JP2007291128A (en) | Transferrin receptor protein of moraxella | |
DE69110082T2 (en) | Subunit vaccine against Actinobacillus Pleuropneumoniae. | |
JP2013505716A (en) | Excessive bleb-forming Shigella strain | |
DK161492B (en) | Process for producing a genetically attenuated bacterial vaccine, and bacterial strain for use in the process | |
EA039487B1 (en) | Combined polysaccharide vaccine compositions and process for production of bacterial capsular polysaccharides | |
US4702911A (en) | Preparation of bacterium pili subunits and vaccines containing pili subunits | |
JP4982009B2 (en) | Neisseria vaccine composition and method | |
US4285931A (en) | E. coli enterotoxin vaccine for veterinary and human use | |
JP2002542169A (en) | Recombinant toxin A / toxin B vaccine against Clostridium difficile | |
KR100221452B1 (en) | Preparation for vaccine composition against enteric infection | |
JPH0840932A (en) | Prophylactic vaccine against staphylococcus infections, it therapeutic antibody and production thereof | |
Chamberlain et al. | Neisseria gonorrhoeae strain MS11 harbouring a mutation in gene aroA is attenuated and immunogenic | |
AU601510B2 (en) | Preparation of bacterium pili subunits and vaccines containing pili subunits | |
CA2203540C (en) | Major outer membrane protein cd of moraxella | |
US5208024A (en) | Vaccine against E. coli septicaemia in poultry | |
JP2002527041A (en) | Vaccine containing recombinant pilin against Neisseria gonorrhoeae or Neisseria meningitidis | |
EP0082072B1 (en) | Process for the production of a biochemical vaccine against salmonella fevers | |
EP0090660A2 (en) | Neisseria gonorrhoeae vaccine | |
NZ206083A (en) | Cattle vaccine against moraxella bovis |